TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Chugai Pharmaceutical Co ( (JP:4519) ) has provided an announcement.
Chugai Pharmaceutical Co., Ltd. announced Eli Lilly’s positive Phase 3 trial results for orforglipron, an oral GLP-1 receptor agonist, which showed significant weight reduction in adults with obesity. The trial demonstrated that orforglipron achieved primary and secondary endpoints, with a safety profile consistent with existing GLP-1 medicines. This development is significant for Eli Lilly’s market positioning in weight management solutions, though it does not impact Chugai’s financial forecast for 2025.
The most recent analyst rating on (JP:4519) stock is a Buy with a Yen7650.00 price target. To see the full list of analyst forecasts on Chugai Pharmaceutical Co stock, see the JP:4519 Stock Forecast page.
More about Chugai Pharmaceutical Co
Chugai Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and distribution of innovative medical products. The company is known for its contributions to healthcare through the creation of novel drugs and therapies, particularly in the fields of oncology, immunology, and infectious diseases.
Average Trading Volume: 2,145,884
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen12098.5B
See more data about 4519 stock on TipRanks’ Stock Analysis page.